Long Term Durability and Safety of Dual IO in NSCLC
Playback speed
10 seconds
ESMO 2022 on the CheckMate 9LA Study Results: Clinical Outcomes in Patients With Tumor PD-L1<1% With 1L Nivo + Ipi + 2 Cycles of Chemo vs. Chemo Alone for mNSCLC
By
ESMO 2022 Conference Coverage
FEATURING
Tom John
By
ESMO 2022 Conference Coverage
FEATURING
Tom John
259 views
October 18, 2022
Login to view comments.
Click here to Login